IQVIA Holdings Inc. $IQV Shares Sold by Price T Rowe Associates Inc. MD

Key Points

• Price T Rowe Associates Inc. has reduced its stake in IQVIA Holdings Inc. by 1.5%, owning about 0.16% of the company, valued at approximately $50 million.
• Analysts are optimistic about IQVIA, with multiple firms raising their target prices significantly, leading to a consensus target price of $228.62.
• IQVIA reported better-than-expected earnings of $2.81 per share for the last quarter, surpassing estimates and showing a revenue growth of 5.3% year-over-year.

Price T Rowe Associates Inc. MD trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 284,069 shares of the medical research company's stock after selling 4,443 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.16% of IQVIA worth $50,082,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. American National Bank & Trust acquired a new stake in IQVIA during the 1st quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd lifted its position in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC lifted its position in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA during the 1st quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. raised its stake in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on IQV shares. Mizuho increased their target price on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Evercore ISI increased their target price on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Redburn Partners set a $188.00 target price on IQVIA in a research note on Friday, May 23rd. Robert W. Baird increased their target price on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, UBS Group increased their target price on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Stock Performance

IQVIA stock opened at $188.05 on Wednesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a fifty day moving average of $174.96 and a two-hundred day moving average of $167.97. The company has a market capitalization of $31.97 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 2.06 and a beta of 1.30. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA's revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.